IN8bio Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

IN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100

IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting

IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024